Elsevier

Lung Cancer

Volume 42, Issue 3, December 2003, Pages 311-318
Lung Cancer

Mediastinal restaging: EUS-FNA offers a new perspective

https://doi.org/10.1016/S0169-5002(03)00364-7Get rights and content

Abstract

Study objective: We hypothesized that transoesophageal endoscopic ultrasound guided fine needle aspiration (EUS-FNA) has the potential to be a valuable and accurate new diagnostic technique for mediastinal restaging in non-small cell lung cancer (NSCLC) after induction chemotherapy. The current restaging modalities either have a low diagnostic accuracy (computed tomography (CT) scan of the thorax) or they are invasive, can be technically difficult and are therefore not commonly performed (remediastinoscopy). Methods and patients: Nineteen consecutive patients with NSCLC and proven ipsilateral or subcarinal lymph node metastases (N2 disease) who had been treated with induction chemotherapy underwent mediastinal restaging by EUS-FNA. Patients had either a partial response (n=14) or stable disease (n=5) based on sequential CT scans of the thorax. Interventions: EUS-FNA was performed in an ambulatory setting with biopsy of mediastinal lymph nodes (LN). No complications occurred. When EUS-FNA restaged the mediastinum as no regional lymph node metastasis (N0), surgical resection of the tumour with lymph node sampling or dissection was performed. Results: The positive predictive value, negative predictive value, sensitivity, specificity and diagnostic accuracy of EUS-FNA in restaging mediastinal LN were 100, 67, 75, 100 and 83%, respectively. Conclusions and significance: EUS-FNA qualifies as an accurate, safe and minimally invasive diagnostic technique for the restaging of mediastinal lymph nodes after induction therapy in NSCLC. In the future EUS-FNA might play an important role in the mediastinal restaging in NSCLC, particularly to identify the subgroup of down staged patients who benefit most from further surgical treatment.

Introduction

Mediastinal restaging in non-small cell lung cancer (NSCLC) after induction chemotherapy remains a major problem. Computed tomography (CT) of the thorax has a low accuracy of only 58% and often overestimates the degree of local tumour regression [1]. Remediastinoscopy has a diagnostic accuracy of 80 respectively, 85% as shown in two small studies (n=24, n=27) [1], [2], however, a high number of incomplete procedures (40%) due to technical difficulties [3]. The current controversy about the effectiveness and implementation of remediastinoscopy in daily practice stimulates the search for alternative restaging methods [4].

Recent studies reported that NSCLC patients with ipsilateral lymph node metastases (IIIA-N2 disease), who were down-staged with induction chemotherapy [no regional lymph node metastasis] had a significantly prolonged survival after surgical resection compared to those with persistent N2 disease [5], [6], [7]. These studies demonstrate that patients without a pathological complete response after induction chemotherapy usually do not benefit from a surgical resection. Although an optimal treatment strategy for IIIA-N2 NSCLC with ipsilateral or subcarinal lymph node metastases is still under investigation, there is increasing evidence that multimodality treatment with induction chemotherapy significantly improves survival [8], [9], [10]. Considering the high prevalence of lung cancer and the poor overall survival of stage IIIA-N2 as a whole, it is a challenge to identify the subgroup of patients who are down-staged by induction chemotherapy to a complete pathologic response. After surgical resection these patients have a 4-year survival of 50% [7]. In addition, unnecessary surgical resection in patients with persistent N2 disease should be avoided. Restaging is important but the current available technique of remediastinoscopy is controversial.

Recently, the minimally invasive technique of transoesophageal endoscopic ultrasound guided fine needle aspiration (EUS-FNA) has become clinically available for the analysis of mediastinal lymph nodes (LN). An ultrasound transducer incorporated on top of an endoscope enables the investigator to visualize and puncture mediastinal LN under real-time ultrasound guidance. The procedure is well tolerated, safe and has a high diagnostic accuracy (89–95%) for the analysis of mediastinal LN [11], [12], [13], [14]. So far, no complications of EUS-FNA in the analysis of mediastinal LN have been reported [11], [12], [13], [14]. The advantages of this technique are multiple: tissue samples are obtained (in contrast to the imaging technique of CT) and the procedure itself is minimally invasive, is performed in an outpatient setting and can be repeated a number of times without technical difficulties (in contrast to mediastinoscopy).

In this preliminary study, we performed restaging of mediastinal lymph nodes with EUS-FNA in 19 patients with NSCLC and proven N2 disease (stadium IIIA) who had been treated with induction chemotherapy. Patients who were restaged by EUS-FNA to N0, underwent surgical resection of the tumour containing lobe or lung and LN sampling or dissection in order to confirm the complete pathologic response. We hypothesized that EUS-FNA has a high diagnostic accuracy in mediastinal restaging and that it is suitable and well tolerated in these patients.

Section snippets

Patients

Nineteen consecutive patients with NSCLC and proven stadium IIIA-N2 disease who had been treated with induction chemotherapy were referred to the Department of Pulmonology of the LUMC for mediastinal restaging by EUS-FNA between February 2001 and March 2003. All patients were accepted regardless of the localisation of the initial lymph node metastasis. Twelve of the 19 patients had previously undergone a mediastinoscopy for staging purposes during the initial lung cancer staging. The induction

Patients

Nineteen patients (6 female, 13 male), mean age 58 years (range 34–73) were included in the study. The primary tumours were predominantly located in the right lung; RUL (n=7), RLL (n=5), LUL (n=2) and LLL (n=5). The various tumour types were: squamous cell carcinoma (n=9), adenocarcinoma (n=7), large cell carcinoma (n=2) and adenosquamous carcinoma (n=1). The initial IIIA-N2 disease was established by mediastinoscopy (n=8), EUS-FNA (n=9), by both diagnostic techniques (n=1) or during

Discussion

We found that in patients with IIIA-N2 disease, EUS-FNA restaged the mediastinal lymph nodes after induction chemotherapy with a diagnostic accuracy of 83%. This is the first report of the concept using EUS-FNA for mediastinal restaging.

There were 3/18 false negative results (Table 1, Table 2). In patient 2 a sampling error must have been occurred as adequate material was aspirated by EUS-FNA from the lower paratracheal station. In patient 9 tumour was found during pneumectomy in a

References (24)

Cited by (118)

  • Endosonography with lymph node sampling for restaging the mediastinum in lung cancer: A systematic review and pooled data analysis

    2020, Journal of Thoracic and Cardiovascular Surgery
    Citation Excerpt :

    The patients who had stable disease or partial response after induction treatment were defined by radiologists through CT or PET/CT. Five studies25-27,29,31 performed EBUS-TBNA alone, and 4 studies23,24,28,30 performed EUS-FNA alone. One study used a combined approach to assess mediastinal lymph node metastases.16

  • Efficacy of Endosonographic Procedures in Mediastinal Restaging of Lung Cancer After Neoadjuvant Therapy: A Systematic Review and Diagnostic Accuracy Meta-Analysis

    2018, Chest
    Citation Excerpt :

    The prevalence of pathologically proven N2 disease ranged from 18.8% to 94%. The neoadjuvant therapy consisted of chemotherapy (at least two cycles) or chemoradiotherapy in five studies14,16-18,21 and three studies5,15,20 respectively; these details were not provided in two studies19,22 (Table 2). The chemotherapy regimen, the dose of radiation, and the number of neoadjuvant therapy cycles varied widely among the included studies.

  • EBUS / EUS: Which relationships? For which result?

    2017, Revue des Maladies Respiratoires Actualites
  • Role of the surgeon in lung cancer staging

    2014, Revue des Maladies Respiratoires Actualites
  • EUS and EBUS in Non–Small-Cell Lung Cancer

    2014, Endosonography, Third edition
View all citing articles on Scopus

Supported by a grant from the Leiden University Medical Center. Technical support from Hitachi Ultrasound.

View full text